scholarly journals NIMG-62. RADIOLOGIC RESPONSE RATE OF IDH MUTANT GLIOMA FOLLOWING RADIATION TREATMENT: A RETROSPECTIVE ANALYSIS

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi156-vi156
Author(s):  
Julie Miller ◽  
Shilpa Tummala ◽  
Tristan Penson ◽  
Tareq Juratli ◽  
Franziska Loebel ◽  
...  
Author(s):  
G. Becker ◽  
R. Lohrum ◽  
F. Hensley ◽  
W. Schlegel ◽  
J. T. Lyman ◽  
...  

2005 ◽  
Vol 23 (7) ◽  
pp. 1365-1369 ◽  
Author(s):  
Anders Jakobsen ◽  
Jens Nederby Nielsen ◽  
Niels Gyldenkerne ◽  
Jan Lindeberg

Purpose To analyze thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism with respect to fluorouracil (FU) sensitivity. Patients and Methods The study included a retrospective analysis of 88 patients with metastatic colorectal cancer and a prospective trial with 51 patients also with measurable metastases. All patients were treated with FU and leucovorin. The analysis of gene polymorphism was performed on normal intestinal tissue and lymphocytes. Results The response rate was significantly higher in patients with TS 3R/3R or MTHFR 677 TT gene polymorphism compared with the other groups. The difference of response rate translated to a difference in time to progression. Similar results were observed in the retrospective analysis and the prospective confirmatory trial. Conclusion The analysis of gene polymorphism allows delineation of a group of patients (30%) with a response rate to a single drug of approximately 50%. This information should be used in the design of tailored treatment.


2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6072-6072 ◽  
Author(s):  
D. I. Kuperman ◽  
B. Nussenbaum ◽  
W. Thorstad ◽  
B. Haughey ◽  
J. Lewis ◽  
...  

6072 Background: Achievement of a partial (PR) or complete (CR) tumor response at the primary site to IC has been used to predict for tumor sensitivity to definitive radiation (RT)-based treatment approaches in patients with LA-HNSCC. Three randomized trials of IC showed that TPF resulted in superior tumor response rates at the primary site in comparison to PF (TAX 323, TAX 324, and GORTEC). Based on the improved tumor response rate with the addition of cetuximab to cisplatin in metastatic HNSCC, TPF-C is a rational approach to improving tumor response rate to IC in LA-HNSCC. Methods: Between 2/06–12/06, 23 consecutive patients with LA-HNSCC were treated with IC that included TPF + cetuximab (400 mg/m2 loading dose followed by 250 mg/m2 weekly dose) for 1–3 cycles, followed by a standardized clinical assessment of tumor response at the primary site and at the regional nodes. TPF (docetaxel and cisplatin both 75 mg/m2 on day 1; 5-FU 750 mg/m2/d for 3 days) was given at every 3 week intervals. PR was defined as = 50% decrease and CR as complete resolution of tumor at the primary site. This is a retrospective analysis of the efficacy and the adverse effects (AE) of TPF-C in these patients. Results: Of 23 patients, 21 were evaluable for tumor response rate (RR). During IC, there were no deaths and grade 3–4 AE included: neutropenic fever (4), sepsis (1), and infusion reactions (4). Patients with favorable (PR or CR) tumor response to IC were treated with definitive RT-based therapy; whereas others were treated with surgery first. Conclusions: In this population of patients with LA-HNSCC with mostly (74%) T3 and T4 primary tumors, the tumor RR at the primary site to TPF-C was 71%. The addition of cetuximab to TPF was feasible. No significant financial relationships to disclose. [Table: see text]


Sarcoma ◽  
2006 ◽  
Vol 2006 ◽  
pp. 1-9 ◽  
Author(s):  
Walter Rhomberg

Purpose. Relatively few results are available in the literature about the radiation response of unresectable sarcomas in relation to their histology. Therefore, an attempt was made to summarize the present situation. Materials and methods. This report is based on a review of the literature and the author's own experience. Adult-type soft tissue sarcomas, chondrosarcomas, and chordomas were analyzed. Radioresponse was mainly associated with the degree of tumor shrinkage, that is, objective responses. Histopathologic responses, that is, the degree of necrosis, are only discussed in relation to radiation treatment reports of soft tissue sarcomas as a group. Results. Radiation therapy alone leads to major responses in about 50% of lipo-, fibro-, leiomyo-, or chondrosarcomas. The response rate is less than 50% in malignant fibrous histiocytomas, synovial, neurogenic, and other rare soft tissue sarcomas. The response rates may increase up to 75% through the addition of radiosensitizers such as halogenated pyrimidines or razoxane, or by the use of high-LET irradiation. Angiosarcomas become clearly more responsive if biologicals, angiomodulating, and/or tubulin affinic substances are given together with radiation therapy. Razoxane is able to increase the duration and quality of responses even in difficult-to-treat tumors like chondrosarcomas or chordomas. Conclusions. The available data demonstrate that the radioresponsiveness of sarcomas is very variable and dependent on histology, kind of radiation, and various concomitantly given drugs. The rate of complete sustained remissions by radiation therapy alone or in combination with drugs is still far from satisfactory although progress has been made through the use of sensitizing agents.


2012 ◽  
Vol 52 (186) ◽  
Author(s):  
S Shrestha ◽  
P Joshi

Introduction: There is no published data in Nepal regarding the use of gefi tinib in patients with non-small cell lung cancer (NSCLC). Therefore, a retrospective analysis was conducted to evaluate the response and toxicity profi le of Gefi tinib alone in patients with advanced NSCLC and unknown epidermal growth factor receptor (EGFR) status. Methods: A single institutional retrospective study was conducted for the period from January 2004 to December 2006 involving patients with locally advanced or metastatic NSCLC who received gefi tinib as monotherapy Primary objective was to evaluate the objective tumor response rate. Results: A total of 36 patients with advanced NSCLC who received gefi tinib 250 mg orally once daily as 1st, 2nd, 3rd, and 4th line treatment in 7, 14, 9, and 6 patients respectively were included in the analysis. Comparable number of patients pertaining to sex, smoking status, and tumor histology were included. The overall response rate at 3 months was 60% including 47% in males and 68% in females. After one month 38% and 6.6% patients with adenocarcinoma and squamous histology respectively responded to gefi tinib therapy. The median progression-free survival was 5.7 months. Toxicities were generally mild with diarrhea, rash and pruritus being the most commonly observed side effects. Conclusion: In this single-center experience, gefi tinib demonstrated clinically signifi cant response in overall population and provided good palliation in pretreated patients. Keywords: Advanced stage NSCLCs, EGFR-TKIs, Gefitinib, monotherapy, Nepal.


Sign in / Sign up

Export Citation Format

Share Document